GGrantIndex
← Leaderboards

Karl B Thor

Duke University

$7,657,909
Attributed
$7,657,909
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.8M · FY201624
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$7,657,909 · 8

By mechanism

R44$5,495,559 · 3
R43$967,191 · 3
R01$925,788 · 1
R41$269,371 · 1

Top collaborators

No co-investigators on record.

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Incontinence

Research focus

IncontinenceCatheterizationPharmaceutical PreparationsBladderUrinationUrinary Tract InfectionCanis FamiliarisMiniature SwineIntestinesUrinary IncontinenceAwakeSpinal Cord InjuryUrineFecesPre-ClinicalMediatingFecal IncontinenceRattusSmall Business Innovation Research GrantFrequenciesFunctional DisorderContractsAnimalsDose

Grant awards (16)

Therapy for Fecal Incontinence and FecalUrgency$391,458
R43 · FY2024 · DK · contact PI
Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia$50,000
R44 · FY2022 · NS · contact PI
Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia$431,363
R44 · FY2021 · NS · contact PI
Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia$941,206
R44 · FY2020 · NS · contact PI
Development of a first-in-class therapeutic for producing 'on-demand' voiding$998,525
R44 · FY2019 · DK · contact PI
Pudendal neuromodulation for incontinence and sphincter dyssynergia after spinal injury$269,371
R41 · FY2019 · NS · contact PI
Development of a first-in-class therapeutic for producing 'on-demand' voiding$1,001,467
R44 · FY2018 · DK · contact PI
An optimized NK2R agonist for 'on-demand' voiding$614,817
R44 · FY2018 · AG · contact PI
An optimized NK2R agonist for 'on-demand' voiding$1,158,181
R44 · FY2017 · AG · contact PI
Development of a first-in-class therapeutic for producing 'on-demand' voiding$300,000
R44 · FY2017 · DK · contact PI
A neurokinin receptor agonist to treat underactive bladder in the elderly$299,989
R43 · FY2017 · AG · contact PI
Identification of an optimized NK2R agonist for 'on-demand' voiding$275,744
R43 · FY2016 · AG · contact PI
PARTURITION INDUCED PELVIC FLOOR NEUROPATHY$231,427
R01 · FY2003 · HD
PARTURITION INDUCED PELVIC FLOOR NEUROPATHY$227,262
R01 · FY2002 · HD
PARTURITION INDUCED PELVIC FLOOR NEUROPATHY$251,229
R01 · FY2001 · HD
PARTURITION INDUCED PELVIC FLOOR NEUROPATHY$215,870
R01 · FY2000 · HD